Laparoscopy can prevent futile primary cytoreductive surgery

January 6, 2017

(HealthDay)—Diagnostic laparoscopy reduces the number of futile laparotomies in women with suspected advanced-stage ovarian cancer, according to a study published online Dec. 28 in the Journal of Clinical Oncology.

Marianne J. Rutten, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues conducted a that involved eight gynecologic centers. Patients with suspected advanced-stage ovarian cancer who qualified for primary cytoreductive surgery (PCS) were randomly assigned to either (102 patients) or primary surgery (99 patients). Laparoscopy guided selection of primary treatment (primary surgery or neoadjuvant chemotherapy followed by interval surgery). Futile laparotomy, defined as a PCS with residual disease of >1 cm, was the primary outcome.

The researchers found that 63 of 102 patients in the laparoscopy group underwent PCS versus 93 of 99 patients in the primary surgery group. Futile laparotomy occurred in 10 percent of those in the laparoscopy group versus 39 percent in the primary surgery group (relative risk, 0.25). Three percent of patients in the laparoscopy group underwent both primary and interval surgery versus 28 percent of patients in the primary surgery group.

"In women with a plan for PCS, these data suggest that performance of diagnostic laparoscopy first is reasonable and that if cytoreduction to <1 cm of residual disease seems feasible, to proceed with PCS," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Laparoscopic approach in early-stage ovarian cancer promising

More information: Full Text

Related Stories

Laparoscopic approach in early-stage ovarian cancer promising

August 13, 2013
(HealthDay)—Operative outcomes of laparoscopic approach in patients with early-stage ovarian cancer may be comparable with those of laparotomy, according to a meta-analysis published in the July issue of the American Journal ...

Neoadjuvant chemotherapy use up in ovarian cancer treatment

September 12, 2016
(HealthDay)—For patients with stage IIIC to IV ovarian cancer, neoadjuvant chemotherapy (NACT) use increased from 2003 to 2012, according to a study published online Sept. 6 in the Journal of Clinical Oncology.

Surgery, chemo best for elderly with advanced ovarian cancer

December 29, 2015
(HealthDay)—Primary debulking surgery and chemotherapy in an optimal timeframe is associated with the longest survival time for elderly women with advanced ovarian cancer, according to a study published in the January issue ...

Recs developed for neoadjuvant chemo in ovarian cancer

August 9, 2016
(HealthDay)—Guidelines have been developed for neoadjuvant chemotherapy use for newly diagnosed, advanced ovarian cancer. The clinical practice guideline was published online Aug. 8 in the Journal of Clinical Oncology.

Robotic surgery may be superior to laparoscopic for uterine CA

November 18, 2015
(HealthDay)—For women with uterine cancer, robotic surgery is more costly but is associated with decreased length of hospital stay and higher rate of lymph node dissection, according to a study published in the November ...

Benefits of single-incision laparoscopy unclear

August 2, 2013
(HealthDay)—There is limited data available to demonstrate the safety and feasibility of minimally invasive, single-incision laparoscopy, according to a technology assessment published in the August issue of Obstetrics ...

Recommended for you

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

February 21, 2018
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...

Research could change how doctors treat leukemia and other cancers fed by fat

February 21, 2018
Obesity and cancer risk have a mysterious relationship, with obesity increasing the risk for 13 types of cancer. For some cancers—including pediatric cancers—obesity affects survival rates, which are lower for people ...

New technique predicts gene resistance to cancer treatments

February 21, 2018
Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.